Metabolism and pharmacokinetics of oxazaphosphorines von Boddy, A V, Yule, S M

Volltext

A Randomized Phase II Pharmacokinetic and Pharmacodynamic Study of Indisulam as Second-Line Therapy in Patients with Advanced Non–Small Cell Lung Cancer von TALBOT, Denis C, VON PAWEL, Joachim, RECK, Martin, CATTELL, Emma, YULE, S. Murray, JOHNSTON, Claire, ZANDVLIET, Anthe S, HUITEMA, Alwin D. R, NORBURY, Chris J, ELLIS, Paul, BOSQUEE, Leon

Volltext

Cyclophosphamide Metabolism in Children with Non-Hodgkin’s Lymphoma von YULE, S. Murray, PRICE, Lisa, MCMAHON, Alex D, PEARSON, Andrew D. J, BODDY, Alan V

Volltext

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam von van Kesteren, Charlotte, Zandvliet, Anthe S, Karlsson, Mats O, Mathôt, Ron A A, Punt, Cornelis J A, Armand, Jean-Pierre, Raymond, Eric, Huitema, Alwin D R, Dittrich, Christian, Dumez, Herlinde, Roché, Henri H, Droz, Jean-Pierre, Ravic, Miroslav, Yule, S Murray, Wanders, Jantien, Beijnen, Jos H, Fumoleau, Pierre, Schellens, Jan H M

Volltext

Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients von Beumer, Jan-Hendrik, Hillebrand, Michel J X, Pluim, Dick, Rosing, Hilde, Foley, Karen, Yule, S Murray, Schellens, Jan H M, Beijnen, Jos H

Volltext

Cyclophosphamide metabolism in children von YULE, S. M, BODDY, A. V, COLE, M, PRICE, L, WYLLIE, R, TASSO, M. J, PEARSON, A. D. J, IDLE, J. R

Volltext

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liqui... von Beumer, Jan Hendrik, Rosing, Hilde, Hillebrand, Michel J. X., Nan-Offeringa, Lianda G. A. H., Foley, Karen, Yule, S. Murray, Heck, Albert J. R., Schellens, Jan H. M., Beijnen, Jos H.

Volltext

Cyclosporin neurotoxicity after chemotherapy von Tweddle, Deborah A, Windebank, Kevin P, Hewson, Quentin Campbell, Yule, S Murray

Volltext

Outcome and toxicity of an ifosfamide-based soft tissue sarcoma treatment protocol in children. the importance of local therapy von Yule, S M, Skinner, R, English, M W, Cole, M, Pearson, A D, Lucraft, H H, Craft, A W

Volltext

Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children von YULE, S. M, PRICE, L, PEARSON, A. D. J, BODDY, A. V

Volltext

Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration von BODDY, A. V, YULE, S. M, WYLLIE, R, PRICE, L, PEARSON, A. D. J, IDLE, J. R

Volltext

Reproducibility of methods relating to cyclophosphamide metabolic studies--Comment\reply von Phillipou, G, Seaborn, C J, Raniolo, E, Yule, S Murray

Volltext

Response von YULE, S. MURRAY, PEARSON, ANDREW D. J., BODDY, ALAN V., IDLE, JEFFREY R.

Volltext

Drug Points: Cyclosporin Neurotoxicity after Chemotherapy von Tweddle, Deborah A., Windebank, Kevin P., Hewson, Quentin Campbell, Yule, S. Murray

Volltext

The Mosquito Fauna of Arizona: Species Composition and Public Health Implications von Jobe, Ndey Bassin, Franz, Nico M, Johnston, Murray A, Malone, Adele B, Ruberto, Irene, Townsend, John, Will, James B, Yule, Kelsey M, Paaijmans, Krijn P

Volltext

Nontechnical skills training in cardiothoracic surgery: A pilot study von Kim, Juka S., Hernandez, Roland A., Smink, Douglas S., Yule, Steven, Jackson, Nicholas J., Shemin, Richard J., Kwon, Murray H.

Volltext

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition von Santo, L, Vallet, S, Hideshima, T, Cirstea, D, Ikeda, H, Pozzi, S, Patel, K, Okawa, Y, Gorgun, G, Perrone, G, Calabrese, E, Yule, M, Squires, M, Ladetto, M, Boccadoro, M, Richardson, P G, Munshi, N C, Anderson, K C, Raje, N

Volltext

First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors von Shapiro, Geoffrey I, Kwak, Eunice, Dezube, Bruce J, Yule, Murray, Ayrton, John, Lyons, John, Mahadevan, Daruka

Volltext

60 Development of a gene signature to predict the anti-tumor response of the salt-inducible kinase (SIK) inhibitor OMX-0407 von Maser, Ilona-Petra, Lacher, Sonja, Stebegg, Marisa, Piras, Vincent, Kracher, Barbara, Quirin, Kai, Yule, Murray, Loferer, Hannes, Bissinger, Stefan

Volltext

Identification of predictive and pharmacodynamic biomarkers associated with the first-in-class selective axl inhibitor bemcentinib across multiple phase II clinical trials von Holt, Robert J, Micklem, David, Brown, Anthony, Yule, Murray, Loges, Sonja, Lorens, James

Volltext